Multicenter, Observational Study of Lanreotide Depot for Treatment of Patients with Acromegaly in the United States

Trial Profile

Multicenter, Observational Study of Lanreotide Depot for Treatment of Patients with Acromegaly in the United States

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SODA
  • Sponsors Ipsen
  • Most Recent Events

    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2016 Interim results assessing extended dosing interval (n = 241) presented at The 98th Annual Meeting of the Endocrine Society.
    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top